{"id":275,"date":"2020-09-04T19:28:25","date_gmt":"2020-09-04T19:28:25","guid":{"rendered":"https:\/\/www.hospitalinnovate.org\/covid19\/?p=275"},"modified":"2020-10-09T00:08:46","modified_gmt":"2020-10-09T00:08:46","slug":"10what-are-the-indications-for-risks-and-benefits-of-empiric-anticoagulation-for-suspected-vte","status":"publish","type":"post","link":"https:\/\/www.hospitalinnovate.org\/covid19\/2020\/09\/04\/10what-are-the-indications-for-risks-and-benefits-of-empiric-anticoagulation-for-suspected-vte\/","title":{"rendered":"10. What are the indications for, risks, and benefits of empiric anticoagulation for suspected VTE?"},"content":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces” equal_height=”yes” content_placement=”bottom” css=”.vc_custom_1599595743669{margin-top: 0px !important;border-bottom-width: 4px !important;padding-top: 0px !important;padding-right: 20px !important;padding-bottom: 0px !important;padding-left: 20px !important;background-color: #f2f2f2 !important;border-bottom-color: #2c5d73 !important;border-bottom-style: solid !important;}”][vc_column width=”2\/3″ css=”.vc_custom_1599247143020{padding-right: 20px !important;padding-left: 10px !important;}”][vc_custom_heading text=”Prevention and Treatment of Venous Thromboembolism Key Clinical Questions” font_container=”tag:h2|text_align:left|color:%23f7941d” use_theme_fonts=”yes” css=”.vc_custom_1599247161415{margin-top: 0px !important;padding-top: 40px !important;}”][\/vc_column][vc_column width=”1\/3″][vc_column_text]<\/p>\n

Home<\/a> \/ VTE Overview<\/a> \/ VTE Clinical Questions<\/a><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row_content_no_spaces” gap=”20″][vc_column width=”3\/4″ css=”.vc_custom_1599595767267{padding: 20px !important;}”][vc_custom_heading source=”post_title” use_theme_fonts=”yes”][vc_column_text]<\/p>\n

a. HOMERuN institutions<\/strong><\/h3>\n

Institutional guidelines on this subject varied greatly. Six institutions (28%) did not address this issue. Fifteen (71%) institutions said they \u201crecommended,\u201d \u201csuggested,\u201d or said to \u201cconsider\u201d empiric therapeutic anticoagulation for patients at high risk for VTE or in whom there was high suspicion of VTE with low bleeding risk when confirmatory testing could not be obtained. The definition of \u201chigh risk for VTE\u201d or \u201chigh suspicion for VTE\u201d varied, including high risk Wells score, refractory hypoxemia, increased dead space, organ failure, physical findings consistent with thrombosis, elevated D-dimer or elevated fibrinogen (varying thresholds), TEG consistent with hypercoagulability, clotting of CRRT, peripheral ischemia, or based on hematology\/multidisciplinary consultation. Two protocols (9.5%) said they \u201cdo not recommend\u201d or \u201cdiscourage\u201d the use of empiric anticoagulation in the absence of confirmed VTE, one of which used the rationale that anticoagulation for DIC has not shown a benefit in the past, though one protocol also left this open in the case of \u201cstrongly suspected thrombosis.\u201d Two protocols (9.5%) suggested consideration of thrombolysis either as part of a clinical trial or empirically for severely ill patients without confirmed thrombosis but with high suspicion for PE, MI, or ischemic stroke.[\/vc_column_text][vc_row_inner gap=”30″ css=”.vc_custom_1599595788387{padding: 20px !important;}”][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

b. What is Known<\/strong><\/h3>\n

There is retrospective evidence of decreased mortality with prophylactic dose heparin-based anticoagulation in the subgroup of patients with D-dimer >6-fold of upper limit of normal or sepsis-induced coagulopathy score \u22654.17<\/a><\/sup>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

c. What is Not Known<\/strong><\/h3>\n

To date, there is no direct evidence for or against empiric therapeutic dose anticoagulation in COVID-19. Trials are underway to investigate different anticoagulation strategies in COVID-19.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=”1\/4″ css=”.vc_custom_1600127155887{border-top-width: 1px !important;border-right-width: 1px !important;border-bottom-width: 1px !important;border-left-width: 4px !important;padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;border-left-color: #2c5d73 !important;border-left-style: solid !important;border-right-color: #2c5d73 !important;border-right-style: solid !important;border-top-color: #2c5d73 !important;border-top-style: solid !important;border-bottom-color: #2c5d73 !important;border-bottom-style: solid !important;border-radius: 4px !important;}”][vc_raw_html]JTVCdWx0aW1hdGVfcG9zdF9saXN0JTIwaWQlM0QlMjIxMjQlMjIlNUQ=[\/vc_raw_html][vc_wp_custommenu nav_menu=”3″ title=”VTE Links” el_class=”subNavButton”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row_content_no_spaces”][vc_column][cesis_line_divider width=””][vc_column_text font_size=”10px” css=”.vc_custom_1602202119452{padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;background-color: #f9f9f9 !important;}”]<\/a><\/p>\n

    \n
  1. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy<\/a>. J Thromb Haemost<\/em>. 2020;18(5):1094-1099. doi:10.1111\/jth.14817<\/li>\n<\/ol>\n

    [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

    Nineteen percent of protocols recommended standard pharmacologic VTE prophylaxis dosing for all COVID-19 patients regardless of estimated VTE risk. Ten percent recommended…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"_links":{"self":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts\/275"}],"collection":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/comments?post=275"}],"version-history":[{"count":8,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts\/275\/revisions"}],"predecessor-version":[{"id":858,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts\/275\/revisions\/858"}],"wp:attachment":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/media?parent=275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/categories?post=275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/tags?post=275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}